Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

ImmunityBio (IBRX) Accumulated Depreciation & Amortization (2016 - 2025)

Historic Accumulated Depreciation & Amortization for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to $11.7 million.

  • ImmunityBio's Accumulated Depreciation & Amortization fell 1308.88% to $11.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.7 million, marking a year-over-year decrease of 1308.88%. This contributed to the annual value of $17.6 million for FY2024, which is 517.5% down from last year.
  • Per ImmunityBio's latest filing, its Accumulated Depreciation & Amortization stood at $11.7 million for Q3 2025, which was down 1308.88% from $7.7 million recorded in Q2 2025.
  • In the past 5 years, ImmunityBio's Accumulated Depreciation & Amortization ranged from a high of $18.5 million in Q4 2023 and a low of $3.0 million during Q1 2021
  • Moreover, its 5-year median value for Accumulated Depreciation & Amortization was $9.4 million (2023), whereas its average is $10.2 million.
  • As far as peak fluctuations go, ImmunityBio's Accumulated Depreciation & Amortization plummeted by 8572.8% in 2021, and later soared by 3761.78% in 2022.
  • Quarter analysis of 5 years shows ImmunityBio's Accumulated Depreciation & Amortization stood at $14.2 million in 2021, then grew by 28.25% to $18.3 million in 2022, then increased by 1.38% to $18.5 million in 2023, then fell by 5.18% to $17.6 million in 2024, then tumbled by 33.58% to $11.7 million in 2025.
  • Its Accumulated Depreciation & Amortization stands at $11.7 million for Q3 2025, versus $7.7 million for Q2 2025 and $3.8 million for Q1 2025.